Makena video gallery

The Makena® (hydroxyprogesterone caproate injection) video gallery has resources for healthcare providers and patients, and covers a variety of topics including risks associated with preterm birth, treatment of Makena for patients who are at risk for recurrent preterm birth, patient experience, and more in-depth information about AMAG Pharmaceuticals’ patient assistance programs.

For healthcare providers

Watch Kate and Dr. Gandell's video about risks of preterm birth

Kate and her healthcare provider discuss her risk for another preterm birth and how she can reduce her risk for another preterm delivery

Once Kate found out she was pregnant again with a single baby, she scheduled an appointment with her doctor to discuss her risk for another preterm birth and how Makena® (hydroxyprogesterone caproate injection) may help reduce her risk.

When Deb, a nurse practitioner, was caring for an uninsured patient who was eligible for Makena, she connected her to Makena Care Connection to ensure affordable access to treatment.

Makena Care Connection® offers personalized support

When Deb, a nurse practitioner, was caring for an uninsured patient who was eligible for Makena, she connected her to Makena Care Connection to ensure affordable access to treatment.

Watch a video that discusses Makena injection best practices

Kristina Sokel, LPN, provides step-by-step instructions for setting patient expectations and administering Makena

Establishing best practices: Proper injection technique for Makena® (hydroxyprogesterone caproate injection)

This easy-to-follow instructional video reviews the proper technique for administering Makena. By creating a sense of calm and comfort, and following the steps outlined when administering therapy, you can help make weekly injections a positive experience.

Download video (90mb)
Watch a video that reviews possible side effects

Review most common and most serious side effects potentially associated with use of Makena

What are the potential side effects of Makena® (hydroxyprogesterone caproate injection)?

It's understandable that your patients may have a lot of questions about taking a medication while pregnant. Learn more about what your patients can expect when receiving Makena injections so you can weigh the benefits and risks associated with therapy.

Watch a video that discusses who might benefit from treatment

See if your patients may benefit from treatment with Makena to reduce the risk of recurrent preterm birth

Find out if Makena® (hydroxyprogesterone caproate injection) is right for your patients

If your patient has delivered a baby too early in the past, she is at an increased risk for another preterm birth. Find out if Makena may be right for her.

Watch a video that explains the differences between compounded products and generic medications

Are compounded products and generic medications the same?

Are compounded products and generic medications the same?

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, describes the differences between FDA-approved drugs (brand and generic) made in accordance with Good Manufacturing Practices (GMPs) and compounded drugs made in a pharmacy.

Watch a video explaining why FDA recommends FDA-approved drugs when medically appropriate

Understand why the FDA recommends FDA-approved drugs when medically appropriate

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, describes the FDA’s statement that FDA-approved medications should be used when medically appropriate rather than compounded formulations, unless there is a specific medical need for the patient.

Watch a video about the FDA statement regarding hydroxyprogesterone caproate

Learn about the FDA statement regarding hydroxyprogesterone caproate

The benefits of FDA approval

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, discusses the differences between FDA-approved medications and treatments that are compounded at pharmacies, and why the FDA recommends using FDA-approved products when medically appropriate.

For patients

Patient Stories

Watch Kate's video

After speaking with her doctor, Kate made a decision to start Makena because she was at risk for another preterm birth. Hear her story.

After speaking with her doctor, Kate made a decision to start Makena® (hydroxyprogesterone caproate injection) because she was at risk for another preterm birth. Hear her story.

Kate gave birth to her son, Gabriel, 5 weeks early (35 weeks). When she became pregnant again with a single baby a year later, she learned she was at risk for another preterm birth and discussed Makena with her healthcare provider.

Watch Heather's video

Meet Heather. She and her healthcare provider chose an FDA-approved product to help lower her chance of having another preterm birth. Hear her story.

Hear why Heather and her healthcare provider chose an FDA-approved product in her fight against recurrent preterm birth

After giving birth to her daughter, Astrid, 5 weeks early, Heather’s doctor told her she was at risk for another preterm birth. Heather and her healthcare provider talked about Makena® (hydroxyprogesterone caproate injection) as a treatment option to help give her second baby a better chance to have more time to develop.

Watch Lyn's video

Meet Lyn. Because she delivered her son early, she was at risk for another preterm birth. Hear her story.

Lyn was surprised to find out she was at risk for another preterm birth due to her history, so she decided to take action

After her older son, Lamar, was born 4 weeks early and spent 19 days in the NICU, Lyn wanted to understand what she could do to help improve her chance of achieving a full‑term pregnancy with her second child.

Watch Katie's video

Meet Katie. She wanted to do what she could to help reduce her risk of delivering another baby too soon. Hear her story.

Understand why receiving FDA-approved Makena® (hydroxyprogesterone caproate injection) was important to Katie

When Katie's water broke unexpectedly at 34 weeks with her first child, she wasn't prepared. Katie wanted to do what she could to help reduce her risk of preterm birth.

Watch Shanise's video

Meet Shanise. Makena Care Connection helped Shanise with the adherence support she needed. Hear her story.

Meet Shanise. Makena Care Connection helped Shanise with the adherence support she needed. Hear her story.

Shanise tragically lost her first son, Prince Xavier, when he was born 18 weeks early. When she got pregnant again, her doctor recommended Makena® (hydroxyprogesterone caproate injection) because she was at risk for another singleton preterm birth. Hear how the Makena Care Connection supported Shanise so she could focus on her goal of a full-term pregnancy without worrying about medication costs.

Watch Sarah's video

Meet Sarah. Hear about the personalized support offered to Sara.

Meet Sarah. Hear about the personalized support offered to Sara.

Sarah gave birth to her first son, David, 6 weeks early (34 weeks). After speaking with her doctor, Sarah chose Makena® (hydroxyprogesterone caproate injection) to help reduce her risk of another singleton preterm birth—and the Makena Care Connection to help ensure her medication was continually available and affordable.

Hear how the Makena Care Connection® supported Nalleli by helping her pay for Makena.

Makena Care Connection® offers personalized support

When Deb, a nurse practitioner, was caring for an uninsured patient who was eligible for Makena, she connected her to Makena Care Connection to ensure affordable access to treatment.

Watch a video where Kate discusses the Makena Care Connection

Makena Care Connection® helped Kate through her prescription process

Kate, a busy mother of a toddler, turned to Makena Care Connection when she was pregnant again with a single baby to help her get started on Makena® (hydroxyprogesterone caproate injection).

About Preterm Birth and Makena

Watch Dr. Gandell's video about preterm birth and Makena

Have you delivered preterm (before 37 weeks) in the past? Listen to an obstetrician to learn more.

Dr. Gandell, a practicing obstetrician for 31 years, explains preterm birth, its risk factors, and how Makena® (hydroxyprogesterone caproate injection) may be able to help reduce the risk of recurrent preterm birth.

Watch Kate and Dr. Gandell's video about risks of preterm birth

Kate and her healthcare provider discuss her risk for another preterm birth and how she can reduce her risk for another preterm delivery

Once Kate found out she was pregnant again with a single baby, she scheduled an appointment with her doctor to discuss her risk for another preterm birth and how Makena® (hydroxyprogesterone caproate injection) may help reduce her risk.

Watch a video that explains the benefits of FDA approval

Understand the benefits of taking an FDA-approved medication

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, describes the FDA’s statement that FDA-approved medications should be used when medically appropriate rather than compounded formulations, unless there is a specific medical need for the patient.

Watch a video that explains the differences between compounded products and generic medications

Are compounded products and generic medications the same?

Are compounded products and generic medications the same?

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, describes the differences between FDA-approved drugs (brand and generic) made in accordance with Good Manufacturing Practices (GMPs) and compounded drugs made in a pharmacy.

Watch a video about the FDA statement regarding hydroxyprogesterone caproate

Learn about the FDA statement regarding hydroxyprogesterone caproate

The benefits of FDA approval

Jennifer Gudeman, PharmD, Vice President of Medical Affairs, Maternal Health, discusses the differences between FDA-approved medications and treatments that are compounded at pharmacies, and why the FDA recommends using FDA-approved products when medically appropriate.

Watch a video on the potential side effects associated with the use of Makena

Review most common and most serious side effects potentially associated with use of Makena

What are the potential side effects of Makena® (hydroxyprogesterone caproate injection)?

It's understandable to have a lot of questions about taking a medication while pregnant. Learn more about what to expect when receiving Makena injections so you and your healthcare provider can discuss if Makena is right for you.

Watch a video on how to identify appropriate patients for Makena

See if you may be a candidate for Makena and talk to your healthcare provider to see if Makena is right for you

Find out if Makena® (hydroxyprogesterone caproate injection) is right for you

If you have delivered a baby too early in the past, you are at an increased risk for another preterm birth. Find out if Makena may be right for you.

Indication

Makena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important Safety Information for Makena (hydroxyprogesterone caproate injection)
  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • The most common adverse reactions reported in ≥2% of subjects and at a higher rate in the Makena group than in the control group were injection site reactions (pain [35% vs. 33%], swelling [17% vs. 8%], pruritus [6% vs. 3%], and nodule [5% vs. 2%]), urticaria (12% vs. 11%), pruritus (8% vs. 6%), nausea (6% vs. 5%), and diarrhea (2% vs. 1%)

Please see full Prescribing Information for Makena.

Important Safety Information and Indication
INDICATION
IMPORTANT SAFETY INFORMATION
Top